Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 8/20 | 0.50 |
| ▸ | F13A1 | P00488 | 5/20 | 0.50 |
| ▸ | RORC | P51449 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TGM1 | P22735 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25298280 | 0.90 | HSD11B1 (0.49) | TGM2F13A1RORCMAPTTGM1 | |
| SCHEMBL309243 | 0.87 | TGM2 (0.64) | TGM2F13A1MAPTTGM1GPR119 | |
| SCHEMBL17102066 | 0.85 | STS (0.55) | TGM2F13A1TGM1GPR119 | |
| SCHEMBL23849996 | 0.84 | ALDH1A1 (0.47) | GAA | |
| SCHEMBL15426424 | 0.80 | HCRTR1 (0.48) | TGM2F13A1RORCMAPTTGFBR1 | |
| SCHEMBL13131400 | 0.79 | GPR119 (0.54) | MAPTGPR119 | |
| SCHEMBL25296539 | 0.78 | F13A1 (0.50) | TGM2F13A1RORCMAPTTGM1 | |
| SCHEMBL17100709 | 0.77 | CYP3A4 (0.60) | TGM2F13A1TGM1NAMPTHSD11B1 | |
| SCHEMBL29060791 | 0.77 | TGM2 (0.64) | TGM2F13A1TGM1GAAHSD11B1 | |
| SCHEMBL485220 | 0.77 | CYP11B2 (0.53) | RORCMAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3883936-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | TGM2 4470/4885F13A1 571/4885RORC 2254/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | TGM2 4660/4885F13A1 1096/4885RORC 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.